Bio News

Ildong Pharmaceutical is conducting a domestic phase 3 trial of fadoprazan, a novel drug targeting the 370 billion won P-CAB market, with patent protection secured through 2046. The drug demonstrated noninferiority to standard treatment in a phase 2 trial and is currently being developed jointly with Daewon Pharmaceutical. Ildong Pharmaceutical plans to complete the phase 3 trial in patients with erosive gastroesophageal reflux disease by the end of 2026.

BIOBOOK TEAM
biobookmedia@biobook.co.krAribio’s AR1001 Meets Primary Endpoint in Phase 3 Alzheimer’s Trial
GC녹십자 Signs MOU With Dongbang FTL to Collaborate on LNP Production
CG Oncology: Cretostimogene Cuts Bladder Cancer Recurrence Risk by 68%; FDA Filing to Expand
CG Oncology: 68% Lower Risk of Bladder Cancer Recurrence; Shares Surge 12%
U.S. FDA Rejects Summit and Akeso’s PD-1/VEGF Lung Cancer Drug
Biogen Signs $411 Million Deal With Trimtech for Neurodegenerative Diseases